YVOMEDICAL
Turnover is estimated at about €550,000, probably between €480,000 and €760,000. The micro format does not state turnover.
Balance sheet
balance sheet total €572,729 on 31-12-2025in euro
in euro
Position in the sector
34.8%
Higher than 29% of the 21,385 companies filing micro accounts in human health (NACE 86) in 2025.
0.72
Higher than 10% of the 20,936 companies filing micro accounts in human health (NACE 86) in 2025.
25.0%
Higher than 58% of the 21,236 companies filing micro accounts in human health (NACE 86) in 2025.
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: bottom quarter
Staff
€57,345
Staff costs divided by the average number of full-time equivalents.
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202119 months |
|---|---|---|---|---|---|---|
| 303,307 | 276,115 | 232,089 | -227,104 | 323,286 | ||
| 247,782 | 254,099 | 226,631 | -234,380 | 263,476 | ||
| 100,557 | 0 | 1,076 | 4,992 | 811,380 | ||
| -1,836 | 24,656 | -111,499 | 113,027 | - | ||
| -85,675 | -278,150 | -441,544 | -268,860 | -103,574 | ||
| 34.8% | 9.2% | -15.5% | -26.1% | 14.1% | ||
| 0.72 | 0.48 | 0.27 | 0.51 | 0.65 | ||
| 1.87 | 9.89 | - | - | 6.11 | ||
| 71.9% | 270.8% | - | - | 89.9% | ||
| 25.0% | 24.9% | 19.9% | -40.4% | 12.6% | ||
| 26.57 | 12.73 | 45.36 | -32.53 | 25.92 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202119 months |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
572,729 | 609,871 | 619,011 | 838,491 | 848,702 | |
21/28 |
348,366 | 352,348 | 454,788 | 556,151 | 655,244 | |
21 |
249,589 | 349,589 | 449,589 | 549,589 | 649,837 | |
22/27 |
98,777 | 2,759 | 5,199 | 6,562 | 5,407 | |
23 |
477 | 969 | 1,461 | 1,953 | 2,446 | |
24 |
98,299 | 1,790 | 3,738 | 4,608 | 2,962 | |
29/58 |
224,364 | 257,523 | 164,223 | 282,341 | 193,457 | |
40/41 |
6,934 | - | 29,364 | 47,755 | 18,049 | |
40 |
- | - | - | 387 | 387 | |
41 |
6,934 | - | 29,364 | 47,367 | 17,662 | |
54/58 |
29,540 | 31,376 | 6,720 | 118,219 | 5,192 | |
490/1 |
187,890 | 226,147 | 128,140 | 116,367 | 170,216 | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
572,729 | 609,871 | 619,011 | 838,491 | 848,702 | |
10/15 |
199,253 | 56,011 | -95,649 | -219,125 | 119,341 | |
10/11 |
12,000 | 12,000 | 12,000 | 12,000 | 12,000 | |
13 |
187,253 | 107,341 | 107,341 | 107,341 | 107,341 | |
133 |
187,253 | 107,341 | 107,341 | 107,341 | 107,341 | |
14 |
- | -63,330 | -214,990 | -338,466 | - | |
16 |
- | - | - | 234,754 | - | |
160/5 |
- | - | - | 234,754 | - | |
164/5 |
- | - | - | 234,754 | - | |
17/49 |
373,476 | 553,860 | 714,660 | 822,862 | 729,361 | |
17 |
63,356 | - | 108,893 | 271,662 | 432,329 | |
170/4 |
63,356 | - | 108,893 | 271,662 | 432,329 | |
42/48 |
310,039 | 535,672 | 605,767 | 551,201 | 297,032 | |
42 |
70,731 | 123,472 | 176,532 | 199,446 | 172,372 | |
44 |
40,495 | 75,364 | 27,363 | 54,269 | 23,610 | |
440/4 |
40,495 | 75,364 | 27,363 | 54,269 | 23,610 | |
45 |
26,492 | 22,243 | 23,094 | 21,802 | 17,305 | |
450/3 |
9,657 | 6,858 | 6,500 | 6,500 | 6,500 | |
454/9 |
16,834 | 15,385 | 16,594 | 15,302 | 10,805 | |
47/48 |
172,321 | 314,593 | 378,778 | 275,684 | 83,745 | |
492/3 |
81 | 18,188 | - | - | - | |
| Income statement | ||||||
9900 |
362,152 | 374,554 | 577,924 | 115,701 | 423,611 | |
62 |
57,345 | 98,439 | 110,858 | 105,483 | 99,479 | |
630 |
104,539 | 102,440 | 103,155 | 104,086 | 156,135 | |
635/8 |
- | - | - | 234,754 | - | |
640/8 |
1,500 | - | 223 | 1,048 | 846 | |
66A |
- | - | 234,754 | 1,520 | - | |
9901 |
198,768 | 173,675 | 128,934 | -331,189 | 167,150 | |
75/76B |
7 | 34 | 0 | 0 | 3 | |
75 |
7 | 34 | 0 | 0 | 3 | |
65/66B |
11,413 | 21,691 | 5,117 | 6,982 | 12,474 | |
65 |
11,413 | 21,691 | 5,117 | 6,982 | 12,474 | |
9903 |
187,361 | 152,018 | 123,818 | -338,171 | 154,679 | |
67/77 |
44,119 | 358 | 341 | 295 | 47,338 | |
9904 |
143,242 | 151,660 | 123,476 | -338,466 | 107,341 | |
9905 |
143,242 | 151,660 | 123,476 | -338,466 | 107,341 | |
| Appropriation of the result | ||||||
9906 |
79,912 | -63,330 | -214,990 | -338,466 | 107,341 | |
14P |
-63,330 | -214,990 | -338,466 | - | - | |
691/2 |
79,912 | - | - | - | 107,341 | |
6921 |
79,912 | - | - | - | 107,341 | |
| Social balance sheet | ||||||
9087 |
1 | 1 | 1 | 1 | 1 | |
Hours worked1013 |
- | - | 1,808 | 1,808 | 19,304 | |
| Document | ||||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 24-08-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankThe accounts were filed on 24-08-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00425076.
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 24-08-2026 | 2026-00425076 | |
| 31-12-2024 | micro format | 17-09-2025 | 2025-00500164 | |
| 31-12-2023 | micro format | 06-10-2024 | 2024-00498249 | |
| 31-12-2022 | micro format | 29-08-2023 | 2023-00409263 | |
| 31-12-2021 | micro format | 26-08-2022 | 2022-20324646 |
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | - | - | 1 | 1 | 1 |
| full-time | - | - | 1 | 1 | 1 |
| part-time | - | - | 0 | - | - |
| in full-time equivalents | 0.5 | - | - | 1 | 1 |
| 0.5 | 0.5 | 1 | 1 | 1 | |
| On a permanent contract | 1 | 1 | 1 | 1 | 1 |
| Joined | - | - | - | - | 1 |
| Left | - | - | - | - | 0 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Overdue debts
tax and social security| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Overdue tax debts | - | - | - | €6,500 | €6,500 |
| Overdue social security (RSZ) debts | - | - | - | - | €10,805 |
Source: notes to the 2021 to 2025 annual accounts (statement of debts)
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | €100,557 | - | €1,076 | €4,992 | €10,380 |
| Intangible fixed assets | - | - | - | - | €801,000 |
| €104,539 | €102,440 | €103,155 | €104,086 | €156,135 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on YVOMEDICAL
The operating result for 2025 is 14% higher than in 2024 and the highest since 2022. It is the third rise in a row.
Debt's share of the balance-sheet total falls from 90.8% to 65.2%. Equity is higher and debt is lower.